VisoMitin® EYE DROPS Skulachev Ion SkQ1

VisoMitin® EYE DROPS Skulachev Ion SkQ1 are based on Skulachev ions SkQ1 - active compounds that protect the energy stations of the mitochondrial cell from oxidative stress.“Skulachev ions”, on the basis of which the active substance of the drug Vizomitin® was created, have unique properties: when they enter cells, they accumulate in the mitochondria. Visomitin® is the world's first registered antioxidant that specifically targets mitochondria.
Visomitin is used for dryness and discomfort in the eyes. Visomitin is used to treat the initial stage of age-related cataracts and dry eye syndrome. Visomitin has antioxidant and keratoprotective effects.

Mitotech is developing several drug formulations of SkQ1 covering a variety of therapeutic areas and methods of administration. The most advanced SkQ1-based drug in Mitotech's development is Visomitin®, which reached Phase III stage in the U.S. for Dry Eye Disease. Multifactorial nature of Dry Eye made this indication a perfect target for SkQ1 as molecule’s mechanism of action addresses gland tissue degeneration, cornea/conjunctiva healing rate and inflammation at the same time.

One of the reasons for the development of age-related cataracts is the damaging effect of ultraviolet radiation, which initiates photo-oxidation processes leading to denaturation of the main structural components of the lens - crystallins. The first protection of eye tissue from ultraviolet radiation is tear fluid, which absorbs ultraviolet light in the range of 240-320 nm and neutralizes it due to the components of the antioxidant activity of tear fluid. According to preclinical studies, the anti-cataract effect of the drug Visomitin® is associated with an increase in the level of expression of the main lens proteins α-crystallins. According to a clinical study, patients with age-related cataracts who used Visomitin® showed an increase in the antioxidant activity of tears.

Indications for use:

As part of complex therapy:

• Symptoms of dry eye syndrome / corneal-conjunctival xerosis (poor tolerance to wind, conditioned air, smoke, foreign body sensation, pain, burning, dry eyes, floating visual acuity, lacrimation, redness of the eyes in the area not covered eyelid).
• Symptoms of the initial stage of age-related cataracts (gradual blurring and decreased visual acuity).

Ingredients:

The active substance of VISOMITIN® Eye drops is plastoquinonyldecyltriphenylphosphonium bromide (PDTP)0.155 μg;
Excipients: Benzalkonium chloride 0.1 mg, hypromellose 2 mg, sodium chloride 9 mg, sodium dihydrogen phosphate dihydrate 0.81 mg, sodium hydrogen phosphate dodecahydrate 1.16 mg, sodium hydroxide 1 M solution to pH 6.0 - 8.0, purified water 1 ml.

Suggested use:

Symptoms of the "dry eye" syndrome: 1-2 drops of the drug in the conjunctival sac 3 times a day. According to clinical studies, the therapeutic effect is achieved in the first 2-4 weeks of use. The therapeutic effect is persistent when used for 6 weeks. If there is no effect during the first 2 weeks of treatment, a specialist examination is required.

The initial stage of age-related cataract: 1-2 drops of the drug into the conjunctival sac 3 times a day. The duration of the course of treatment is 6 months. The diagnosis of "the initial stage of age-related cataract" must be established by a specialist. If there is no improvement after treatment, or the symptoms worsen or new symptoms appear, you should consult your doctor. Use the drug only according to the indications, the route of administration and the doses indicated in the instructions for use.
One bottle is designed for use 3 times a day, 1-2 drops for 24 days.

Special instructions:

Contact lenses: Visomitin® eye drops contain benzalkonium chloride as a preservative and are not recommended for use when wearing contact lenses. Before instilling eye drops, contact lenses should be removed and put back on no earlier than 15 minutes after using the drug.
The bottle must be closed after each use.
Do not touch the eye with the tip of the pipette while instilling.
The active ingredient of Visomitin® is very sensitive to light: between uses, do not store the bottle in a lighted place!

Storage conditions:

In a dark place at a temperature from +2 to +8°C.
Store the opened bottle in a dark place at a temperature from +2 to +8°C; use within 1 month.
Keep out of the reach of children!

Interaction with other drugs:

There have been no previously reported adverse interactions between Visomitin® and other drugs. If necessary, it can be used simultaneously with other eye drops;
the interval between instillations should be at least 15 minutes.

Contraindications:

Hypersensitivity to the components of the drug.
Children under 18 years of age (no clinical trial data available).

Contains:

5 ml

Guaranteed authenticity and quality:

100% Original from the Mitotech (Russian Federation)

Development and production:

Mitotech (Russian Federation)

Mitochondrial antioxidants of targeted action based on Skulachev ions developed by MITOTECH company together with the Moscow State University named after M.V. Lomonosov. SkQ is a class of mitochondria-targeted antioxidants developed under the leadership of academician Vladimir Skulachev. In 2005, the group of academician V.P. Skulachev developed a new mitochondrial-targeted antioxidant. In order to fundamentally increase its effectiveness, plastoquinone was used - a substance from the most oxygen-saturated place in living nature - plant chloroplasts. The substance SkQ1 was designed and synthesized, the effectiveness of which was hundreds of times higher than previous analogues.

Produced by FIRN M by order of Mitotech (Russian Federation)

The biotechnology company FIRN M was established at the USSR Academy of Sciences in 1989. The company’s main activity is the development and production of medicinal products. Today, FIRN M is one of the most dynamically developing biotech companies in Russia. The company occupies a leading position in the Russian market for the development and production of ophthalmological drugs.